

Express Mail No. EV 544892821 US

SEP 22 2004

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10271-053-999

APPLICATION NO.

10/091,236

APPLICANT

Dingivan and Wilder

FILING DATE

March 4, 2002

GROUP

1651

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
PC	B01	WO 03/075957	9/18/03	PCT			
	B02	WO 03/0068320	4/10/03	PCT			
	B03	WO 03/0044406	3/6/03	PCT			
	B04	WO 02/069904	9/12/02	PCT			
	B05	WO 00/78815	12/28/00	PCT			
	B06	WO 00/78814	12/28/00	PCT			
	B07	WO 00/31248	6/2/00	PCT			
	B08	WO 99/03502	1/28/99	PCT			
	B09	WO 98/46264	10/22/98	PCT			
	B10	WO 98/40488	9/17/98	PCT			
	B11	WO 98/33919	8/6/98	PCT			
	B12	WO 98/23289	6/4/98	PCT			
	B13	WO 97/34631	9/25/97	PCT			
	B14	WO 95/25543	3/9/95	PCT			
	B15	WO 93/08656	4/29/93	PCT			
	B16	WO 89/05155	6/15/89	PCT			
	B17	EP 555880	8/18/93	EP			

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	GenBank AF018081 Human type XVIII collagen (COL18A1) m RNA, alternatively spliced, long form, complete cds (1998)
	C02	GenBank AF018082 Human type XVIII collagen (COL18A1) m RNA, alternatively spliced, short form, complete cds (1998)
	C03	GenBank AH002740 human T-cell surface antigen T11 (CD2) gene, exon 1, clone PB2 (2002)
	C04	GenBank CAA29622 (1993)
	C05	GenBank E12817 cDNA encoding human LFA-3 (1998)
	C06	GenBank M16445 human surface antigen CD2 mRNA, complete cds (1994)
	C07	GenBank NM_000301 human plasminogen (PLG), mRNA (2003)

Philip B. Gumpel

- 1 -

NYID: 1544415.1

6/14/06

MU	C08	GenBank X06143 murine mRNA for T11 protein (iaas)
SEP 12 2004 FBI LABORATORY	C09	Abrams et al., 2000, "Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells," J. Exp. Med. 192(5):681-694
SEP 12 2004 FBI LABORATORY	C10	Adkins et al., 2000, "A phase I placebo-controlled, randomized, dose-escalation safety study of MEDI-507, a humanized anti-CD2 monoclonal antibody, in the initial treatment of at least grade II acute graft-versus-host disease," Itinerary for the American Society of Hematology 42 nd Annual Meeting 12/4/00, Blood 96:476A Poster Board No. 784
	C11	Ashcroft et al., 2000, "Therapeutic strategies for psoriasis," J. Clin. Pharm. Ther. 25(1):1-10
	C12	Ashkenazi et al., 1991, "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin," Proc. Natl. Acad. Sci. USA 88:10535-10539
	C13	Bathon et al., 2000, "A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis," N. Eng. J. Med. 343:1586-1593
	C14	Besse et al., 1997, "Prevention of rejection with BTI-322 after renal transplantation (Results at 9 months)," Transplantation Proc. 29:2425-2426
	C15	Branco et al., 1999, "Selective deletion of antigen-specific, activated T cells by a humanized MAB to CD2 (MEDI-507) is mediated by NK cells," Transplantation 68(10):1588-1596
	C16	Chisholm et al., 1994, "The effects of an immunomodulatory LFA3-IgG ₁ fusion protein on nonhuman primates," Therapeutic Immunity 1:205-216
	C17	Cockett et al., 1990, "High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification," Biotechnology 8:662-667
	C18	Couriel et al., 2000, "Infliximab for the treatment of graft-versus host disease in allogeneic transplant recipients: an update," Itinerary for the American Society of Hematology 42 nd Annual Meeting, 12/4/00, Poster board Number 775
	C19	Davis et al., 1996, "The structure and ligand interactions of CD2: Implications for T-cell function," Immunology Today 17(4):177-187
	C20	Dehoux et al., 2000, "Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody," Transplantation 69(12):2622-2633
	C21	De La Parra et al., 1991, "Inhibition of T-Cell Activation by Lo-CD2-a, A rat monoclonal antibody against the human CD2 glycoprotein," Belgian Journal of Zoology 121(Supp. 1):13 Abstract 16
	C22	Diasio et al., 1996, "Immunomodulators: Immunosuppressive agents and immunostimulants," in: The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, Ch. 52, pp. 1291-1306
JH	C23	Disepio et al., 2000, "New drugs in the treatment of psoriasis," Expert Opin. Investig.

Pharm Gamma 15-2-1
6/14/06

DIPE		Drugs 9(1):79-93
SEP 7 2004	C34	Dumont et al., 1998, "Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T cells," J. Immunol. 3797-3804.
	C25	Durie et al., 1994, "The role of CD40 in the regulation of humoral and cell-mediated immunity," Immunol. Today 15(9):406-411
	C26	Ellis, 1999, "Quality of Life (QOL) of Amevive™ (LFA3TIP) in patients with chronic plaque psoriasis," Amevive Breakfast Meeting, 12/3/99 and abstract from Br. J. Dermatol. 141:990 Abstract 82
	C27	Ellis et al, "Quality of Life (QOL) in patients with chronic plaque psoriasis treated with Amevive (LFA3TIP)," Poster Presentation
	C28	Feldmann et al., 1999, "Cytokine Inhibitors: Biologics," Inflammation: Basic Principles and Clinical Correlates, 3 rd ed., Gallin and Snyderman, eds. Lippincott, Williams, & Wilkins, Philadelphia, pp. 1207-1212
	C29	Ferrant et al., 1997, "LO-CD2a/BTI322 for steroid resistant graft-versus host disease," BTI Ref. 1979 Transplant 19(Supp. 1):S181 Abstract P721
	C30	Fredriksson and Pettersson, 1978, "Severe psoriasis - oral therapy with a new retinoid," Dermatologica 157(4):238-244
	C31	Griffiths, 1999, "T cell targeting for psoriasis," Amevive Breakfast Meeting 12/3/99
	C32	Jooss et al., 1996, "Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung," Hum. Gene Ther. 7:1555-1566
	C33	Kaplon et al., 1996, "Short course single agent therapy with an LFA-3-IgG ₁ fusion protein prolongs primate cardiac allograft survival," Transplantation 61(3):356-363
	C34	Kohno et al., 1990, "A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor," Proc. Natl. Acad. Sci. USA 87:8331-8335
	C35	Kozarsky et al., 1993, "An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites," Cell Immunol. 150(2):235-246
	C36	Krogh et al., 1999, "Models to study the pathogenesis of thyroid autoimmunity," Biochimie 81:511-515
	C37	Krueger et al., 2000, "Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking," J. Invest. Dermatol. 115(2):333
	C38	Krueger, 1999, "Efficacy and safety results of a phase II trial with LFA3TIP in patients with chronic plaque psoriasis," Amevive Breakfast Meeting 12/3/99
	C39	Krueger, 1999, "Phase II trial results of Amevive™ (LFA3TIP) in patients with chronic plaque psoriasis," Br. J. Dermatol. 141:979-980, Abstract 39

Philip G. Miller - 3 -
6/12/06




	C40	Krueger et al., 2000, "Successful in vivo blockade of CD25 (High-affinity interleukin 2 receptor) on T-cells by administration of humanized anti-Tac antibody to patients with psoriasis," J. Am. Acad. Dermatol. 43(3):448-458
	C41	Latinne et al., 1996, "An anti-CD2 mAb induces immunosuppression and hyporesponsiveness of CD2+ human T cells in vitro," Int. Immunol. 8(7):1113-1119
	C42	Lerut et al., "The use of tacrolimus (TAC) and anti-CD2 antibody Lo-CD2a (BTI-322) in adult liver transplantation (LT): Preliminary results of a prospective randomized study," Abstract 102
	C43	Li et al., 1995, "CD2 Antigen: Signaling features and strategies to inhibit CD2 antigen-derived signals," in Recent Devel. Trans. Med. Vol. 2, Ch. 7, Salomon and Sollinger, eds., pp. 97-121
	C44	Linden et al., 1999, "Psoriasis: Current perspectives with an emphasis on treatment," Am. J. Med. 107(6):595-605
	C45	Lipsky et al., 2000, "Infliximab and methotrexate in the treatment of rheumatoid arthritis," N. Engl. J. Med. 343(22):1594-1602
	C46	Lopez-Berestein et al., 1989 in: Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fiedler, eds., Alan R. Liss, NY, pp. 353-365 or 317-327
	C47	Magilavy et al., "Immunopharmacologic effects of AMEVIVE™ (LFA3TIP) in chronic plaque psoriasis: Selectivity for peripheral memory effector (CD45RO+) over naïve (CD45RA+) T cells," Poster presentation and abstract from Br. J. Dermatol. 141:990, Abstract 81
	C48	Magilavy et al., 2000, "The Response of Plaque Psoriasis to Amevive™ (LFA3TIP) and the Selective Suppression of Memory/Effector T Cells (CD45RO+) Verses Naïve T Cells (CD45RA+) Is Serum Levels of LFA3TIP," J. Invest. Dermatol. 114(4):776 Abstract 148
	C49	Magilavy et al., 1999, "Pharmacodynamic effects of Amevive™ (LFA3TIP), a LFA-3/igg Fc fusion protein in chronic plaque psoriasis: selectivity for peripheral memory-effector (CD45RO+) over naïve (CD45RA+) T cells," Ameveive Breakfast Meeting, 12/3/99
	C50	Majeau et al., 1994, "Mechanism of Lymphocyte Function-Associated Molecule 3-Ig Fusion Proteins Inhibition of T Cell Responses," J. Immunol. 152(6):2753-67
	C51	Meier et al., 1995, "Immunomodulation by LFA3TIP, an LFA-3/IgG1 Fusion Protein: Cell Line Dependent Glycosylation Effects on Pharmacokinetics and Pharmacodynamic Markers," Ther. Immunol. 2(3):159-171
	C52	The Merck Manual of Diagnosis and Therapy, 1999, 17 th ed., Beets and Berkow, eds., Merck Research Laboratories, Whitehouse Station, NJ pp. 416-423
	C53	Miller et al., 1993, "Specific Interaction of Lymphocyte Function-Associated Antigen 3 with CD2 Can Inhibit T Cell Responses," J. Exp. Med. 178:211-222
	C54	Mollereau et al., 1999, "Effects of Anti-CD2 Monoclonal Antibody: CD2- and CD95-Mediated Apoptosis of Human Peripheral T Cells," Transplantation Proc. 31:1245

PHILIP GAMBIA 6/14/06

10/091236

<p>SIPE</p> <p>NG</p> <p>SEP 12 2004</p> <p>RECEIVED</p>	<p>C55</p> <p>C56</p> <p>C57</p> <p>C58</p> <p>C59</p> <p>C60</p> <p>C61</p> <p>C62</p> <p>C63</p> <p>C64</p> <p>C65</p> <p>C66</p> <p>C67</p> <p>C68</p> <p>C69</p> <p>C70</p>	<p>Mourad et al., 1997, "BTI-322 for Acute Rejection After Renal Transplantation," Transplantation Proc. 29:2353</p> <p>Nizet et al. 2000, "The experimental (in vitro) and clinical (in vivo) immunosuppressive effects of a rat IgG2b anti-human CD2 mAb, LO-CD2a/BTI-322," Transplantation 69(7):1420-1428</p> <p>Order et al., eds., 1985, "Analysis and future prospective of the therapeutic use of radiolabeled antibody in cancer therapy," in: Monoclonal Antibodies for Cancer Detection and Therapy, Academic Press, pp. 303-316</p> <p>Oswald et al., 1992, "Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation," Proc. Natl. Acad. Sci. USA 89:8676-8680</p> <p>Paul, ed., 1989, Fundamental Immunology 2nd Ed., Raven Press, NY, pp. 332-336</p> <p>Peters et al., 2000, "Pathophysiology and treatment of psoriasis," Am. J. Health Sys. Pharm. 57(7):645-659</p> <p>Przepiorika et al., "Pharmacokinetics and Safety of BTI-322, a Rat Anti-CD2 Monoclonal Antibody for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," BTI Ref 3623</p> <p>Przepiorka et al., 1998, "A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease," Blood 92(11):4066-4071</p> <p>Rabinowitz et al., 1995, "In vitro activation leads to the binding of T-cell markers to the surface of B-lymphocytes," Clin. Immunol. Immunopathol. 76(2):148-154</p> <p>Ratanathathorn et al., 1999, "Pharmacokinetics and Safety of Medi-507, a Humanized Anti-CD2 Monoclonal Antibody in Severe Steroid-Resistant Graft-Versus-Host Disease," International Society for Experimental Hematology, Abstract 119</p> <p>Roenigk et al., 1988, "Methotrexate in psoriasis: revised guidelines," J. Am. Acad. Dermatol. 19(1 pt. 1):145-156</p> <p>Rosenberg and Gallin, 1999, "Inflammation," in: Fundamental Immunology 4th Ed., Paul, ed., Lippincott-Raven Publishers, Phila., pp. 1051-1066(Chapter 32)</p> <p>Rouleau et al., 1997, "CD2 Induced Apoptosis of Peripheral T Cells," Transplantation Proc. 29:2377-2378</p> <p>Schad et al., 1996, "An Anti-CD2 Monoclonal Antibody That Elicits Alloantigen-Specific Hyporesponsiveness," Transplantation Proceedings 28(4):2051-2053</p> <p>Seckinger et al., 1990, "Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor," Proc. Natl. Acad. Sci. USA 87:5188-5192</p> <p>Sultan et al., 1997, "Blockade of CD2-LFA-3 Interactions Protects Human Skin Allografts in Immunodeficient Mouse/Human Chimeras," Nature Biotechnology 15:759-762</p>
--	---	--

7Huep/Gamb
16/12/06

	C71	Thorbecke et al., 1992, "Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice," Proc. Natl. Acad. Sci. USA 89:7375-7379
	C72	Vie et al., 1992, "Human fusion proteins between interleukin 2 and IgM heavy chain are cytotoxic for cells expressing the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA 89(23):11337-11347
	C73	Williams et al., 1994, "Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis," Proc. Natl. Acad. Sci. USA 91:2762-2766
	C74	Wu et al., 1998, "Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb," Proc. Natl. Acad. Sci. USA 95(11):6037-6042
	C75	Xu et al., 2000, "Inhibition of Human Anti-Pig T Cell Response by Anti-CD2, Anti-CD40L, and CTLA4-Ig: A Comparative Study," Transplantation Proc. 32:926
	C76	Yokota et al., 1986, "Isolation and characterization of a human interleukin cDNA clone, homologous to mouse B-cell stimulatory factor 1, that expresses B-cell- and T-cell-stimulating activities," Proc. Natl. Acad. Sci. USA 83:5894-5898
EXAMINER 		DATE CONSIDERED 6/14/06
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		



~~1651~~

1644


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
OC	A01	60/316,321		Wilder			8/31/01
	A02	09/339,222		Huse and Wu			6/24/99
	A03	09/081,522		Huse			5/19/98
	A04	2001/0011125	8/2/01	Huse, W.			
	A05	6,596,850	7/22/03	Huse			
	A06	6,590,079	7/8/03	Huse			
	A07	6,171,787	1/9/01	Wiley			
	A08	6,171,588	1/9/01	Carron et al.			
	A09	6,162,432	12/19/00	Wallner et al			
	A10	6,160,099	12/12/00	Jonak et al.			
	A11	6,153,628	11/28/00	Jin et al.			
	A12	6,130,231	10/10/00	Wityak et al.			
	A13	6,114,517	9/5/00	Monia et al.			
	A14	6,096,707	8/1/00	Heino et al.			
	A15	6,090,944	7/18/00	Hutchinson			
	A16	6,048,861	4/11/00	Askew et al.			
	A17	6,036,978	3/14/00	Gombotz et al.			
	A18	5,994,510	11/30/99	Adair et al.			
	A19	5,985,278	11/16/99	Mitjans et al.			
	A20	5,968,741	10/19/99	Plevy et al.			
	A21	5,959,087	9/28/99	Rathjen et al.			
	A22	5,958,412	9/28/99	Welt et al.			
	A23	5,955,572	9/21/99	Ruoslahti et al.			
	A24	5,951,983	9/14/99	Bazin et al.			
	A25	5,928,643	7/27/99	Wallner et al.			
	A26	5,919,452	7/6/99	Le et al.			
	A27	5,914,111	6/22/99	Wallner et al.			
	A28	5,849,692	12/15/98	Jonczyk et al.			

THURP GmD 6/12/06

10/02/236

A29	5,830,678	11/3/98	Carter						
A30	5,817,457	10/6/98	Bird et al.						
A31	5,817,311	10/6/98	Bazin et al.						
A32	5,808,029	9/15/98	Brockhaus et al.						
A33	5,780,426	7/14/98	Palladino et al.						
A34	5,770,565	6/23/98	Cheng et al.						
A35	5,767,071	6/16/98	Palladino et al.						
A36	5,753,230	5/19/98	Brooks et al.						
A37	5,741,488	4/21/98	Feldman et al.						
A38	5,736,138	4/7/98	Pfizenmaier et al.						
A39	5,730,979	3/24/98	Bazin et al.						
A40	5,728,677	3/17/98	Wallner et al.						
A41	5,705,481	1/6/98	Jonczyk et al.						
A42	5,698,195	12/16/97	Le et al.						
A43	5,693,612	12/2/97	Jonczyk et al.						
A44	5,658,746	8/19/97	Coan et al.						
A45	5,656,272	8/12/97	Le et al.						
A46	5,652,110	7/29/97	Kim et al.						
A47	5,652,109	7/29/97	Kim et al.						
A48	5,644,034	7/1/97	Rathjen et al.						
A49	5,610,279	3/11/97	Brockhaus et al.						
A50	5,589,570	12/31/96	Tamura et al.						
A51	5,578,704	11/26/96	Kim et al.						
A52	5,547,853	8/20/96	Wallner et al.						
A53	5,523,209	6/4/96	Ginsberg et al.						
A54	5,498,694	3/12/96	Ruoslahti						
A55	5,478,725	12/12/95	Lessey						
A56	5,436,154	7/25/95	Barbanti et al.						
A57	5,426,181	6/20/95	Lee et al.						
A58	5,360,716	11/1/94	Ohmoto et al.						
A59	5,334,380	8/2/94	Kilbourn et al.						
A60	5,306,620	4/26/94	Ginsberg et al.						
A61	5,262,520	11/16/93	Plow et al.						
A62	5,231,024	7/27/93	Moeller et al.						
A63	5,223,395	6/29/93	Gero						
A64	5,204,445	4/20/93	Plow et al.						

Handwritten: 6/14/06



W/ OA 22/6

A65	5,196,511	3/23/93	Plow et al.				
A66	5,149,780	9/22/92	Plow et al.				
A67	5,147,638	9/15/92	Esmon et al.				
A68	5,136,021	8/4/92	Dembinski et al.				
A69	5,017,691	5/21/91	Lee et al.				
A70	4,658,019	4/14/87	Kung et al.				

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

? HUP GANDER 6/14/06

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.